Pernix Therapeutics to Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013

  Pernix Therapeutics to Report Fourth Quarter and Full Year 2012 Financial
  Results on March 18, 2013

      Management to Host a Conference Call on March 18 at 9:00 a.m. EST

Business Wire

THE WOODLANDS, Texas -- March 5, 2013

Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical
company, today announced that it will release its fourth quarter and full year
2012 financial results before the U.S. stock market opens on Monday, March 18,
2013 and has scheduled a conference call at 9:00 am EST that day to discuss
the financial results.

The conference call will feature remarks by Cooper Collins, President and
Chief Executive Officer, and David Becker, Chief Financial Officer. To
participate in the conference call, please dial (888) 510-1786 (domestic) or
(719) 785-1753 (international). Participants can reference the passcode
5442195. Please dial in approximately 5 minutes prior to the call.

The conference call will also be available via a live listen-only webcast and
can be accessed through the Investor Relations section of the Company’s
website, www.pernixtx.com. Please allow extra time prior to the call to visit
the Company’s website and download any software that may be needed to listen
to the webcast.

A replay of the conference call will be available through March 25, 2013, at
(888) 203-1112 (domestic) or (719) 457-0820 (international). The passcode for
the replay is 5442195. An online archive of the webcast will be available on
the Company's website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company manages a portfolio of branded
products, including the recently acquired Hawthorn Pharmaceuticals’ product
line. The Company’s branded products for the pediatrics market include CEDAX®,
an antibiotic for middle ear infections, NATROBA™, a topical treatment for
head lice marketed under an exclusive co-promotion agreement with ParaPRO,
LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX®
and PEDIATEX®). The Company’s branded products for gastroenterology include
OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer
disease, and REZYST™, a probiotic blend to promote dietary management. The
Company promotes its branded pediatric and gastroenterology products through
its sales force. Pernix markets its generic products through its wholly-owned
subsidiaries, Cypress Pharmaceutical and Macoven Pharmaceuticals. The
Company’s wholly-owned subsidiary, Great Southern Laboratories, manufactures
and packages products for the pharmaceutical industry in a wide range of
dosage-forms. A product candidate utilizing cough-related intellectual
property is in development for the U.S. OTC market. Founded in 1996, the
Company is based in The Woodlands, TX.

Additional information about Pernix is available on the Company’s website
located at www.pernixtx.com.

Contact:

Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, (800) 793-2145 ext. 3002
Director, Investor Relations
jschepers@pernixtx.com